Zanubrutinib, rituximab and lenalidomide induces deep and durable remission in TP53-mutated B-cell prolymphocytic leukemia: a case report and literature review

Haematologica. 2022 May 1;107(5):1226-1228. doi: 10.3324/haematol.2021.280259.

Authors

Lijie Xing¹, Qiang He¹, Linna Xie¹, Hui Wang¹, Zengjun Li²

Affiliations

¹ Department of Hematology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan.
² Department of Hematology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan. zengjunli@163.com.

No abstract available

Publication types

Case Reports
Review
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Humans
Lenalidomide / therapeutic use
Leukemia, Prolymphocytic, B-Cell* / drug therapy
Piperidines
Pyrazoles
Pyrimidines / therapeutic use
Rituximab / therapeutic use
Tumor Suppressor Protein p53 / genetics

Substances

Piperidines
Pyrazoles
Pyrimidines
TP53 protein, human
Tumor Suppressor Protein p53
Rituximab
zanubrutinib
Lenalidomide

Grants and funding

Funding: this investigation was supported by the grant ZR2021MH072 to LX from Shandong Provincial Natural Science Foundation, China.